Precigen reports Q3 EPS (9c), consensus (8c)

Reports Q3 revenue $953K vs. $1.38M a year ago. “The strategic reprioritization of our portfolio announced last quarter has enabled us to focus our team and allocate resources to advance PRGN-2012 as rapidly as possible. We are excited about our imminent submission of a BLA for PRGN-2012 in RRP as we have finalized our pre-BLA meetings and are aligned with the FDA on the content for all modules and plan for submission in Q4. Our commercial and manufacturing readiness campaigns for PRGN-2012 are well underway to support a potential 2025 launch,” said Helen Sabzevari, CEO. “Following our reprioritization and public equity offering announced in August, we remain focused on fiscal management while appropriately investing in activities necessary for the potential launch of PRGN-2012. We are making good progress on a number of potential financing options, including strategic partnerships and other transactions..,” said Harry Thomasian Jr., CFO.